NYSE$ELAN
Elanco Animal Health Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Elanco's Q3 2023 financial results were reported, showcasing revenue growth and strategic advancements.
Elanco Animal Health reported a revenue of $1,068 million, a 4% increase, and a net loss of $1,096 million, which included a $1,042 million non-cash goodwill impairment charge. Adjusted EPS was $0.18, and adjusted EBITDA reached $214 million. The company is updating its full-year guidance to reflect its third-quarter performance and the impact of foreign exchange rates.
- Revenue reached $1,068 million, reflecting a 4% reported growth or 5% excluding foreign exchange impacts.
- A reported net loss of $1,096 million was inclusive of a $1,042 million non-cash goodwill impairment charge.
- Adjusted EBITDA was $214 million, representing 20.0% of revenue.
- Innovation pipeline remains on track with potential blockbuster products Credelio Quattro, Bovaer and Zenrelia.
Headline financials
Revenue & EPS history
Elanco · Revenue · Quarterly
$1.07B
Revenue by segment
Elanco · $1.58B total across 5 segments · Q3 2023
- Farm Animal$561M—35.6%
- Pet Health$495M+5.1%31.4%
- Cattle$242M+3.9%15.4%
- Poultry$184M+15.7%11.7%
- Swine$93M+10.7%5.9%
Forward guidance
Elanco is updating its full year 2023 guidance to reflect third quarter outperformance offset by expected unfavorable impact of foreign exchange rates.
Tailwinds
- Revenue of $4,360 to $4,400 million, constant currency growth improves to flat to 1%.
- Adjusted EPS of $0.88 to $0.94
- Adjusted EBITDA of $965 to $1,000 million
- Net leverage ratio expected at 5.5x to 5.8x Adjusted EBITDA at year-end 2023
- Company expects revenue growth of 1% to 4% on a constant currency basis in Q4 2023.
Headwinds
- Reported Net Loss of $1,174 to $1,204 million
- Reported diluted EPS of $(2.43) to $(2.37)
- Revenue guidance for the fourth quarter includes an estimated headwind of approximately $10 million from the unfavorable impact of foreign exchange rates compared to the prior year.
- The impact of foreign exchange on revenue is now expected to be a headwind of approximately $70 million, a $40 million increase from the August guidance.
- Full year reported net loss guidance does not include any further goodwill impairment beyond the third quarter charge.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+2.0%
Avg return
Earnings day
+2.8%
Avg return
5 days after
+1.1%
Avg return
30 days after
52%
16 / 31 earnings
Positive
+27.2%
Q1 2024
Best reaction
-16.3%
Q2 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +13.9% | -5.6% | +2.6% | |
| Q4 2025 | +7.3% | +6.7% | -0.7% | |
| Q3 2025 | -4.2% | -1.0% | -2.7% | |
| Q1 2025 | +26.2% | +34.8% | +46.2% | |
| Q4 2024 | -3.7% | +0.5% | -2.7% | |
| Q3 2024 | +9.4% | +9.8% | -2.8% | |
| Q2 2024 | +5.3% | +12.6% | +21.9% | |
| Q1 2024 | +27.2% | +25.7% | +34.7% | |
| Q4 2023 | +0.5% | -2.1% | -1.2% | |
| Q3 2023 | +15.9% | +14.1% | +36.4% | |
| Q2 2023 | +7.0% | +4.5% | +2.7% | |
| Q1 2023 | -3.8% | -8.4% | -0.1% | |
| Q4 2022 | -6.9% | -11.0% | -33.1% | |
| Q3 2022 | -10.3% | +0.4% | -6.7% | |
| Q2 2022 | -1.6% | +3.3% | -23.9% | |
| Q1 2022 | -7.9% | -6.4% | +1.5% | |
| Q4 2021 | +8.2% | +12.4% | +3.3% | |
| Q3 2021 | +1.2% | +0.3% | -14.3% | |
| Q2 2021 | -16.3% | -12.3% | -4.2% | |
| Q1 2021 | +3.8% | +3.4% | +10.1% | |
| Q4 2020 | +2.8% | +9.0% | -9.8% | |
| Q3 2020 | -4.7% | -8.0% | -9.8% | |
| Q2 2020 | +11.7% | +17.3% | +37.7% | |
| Q1 2020 | -13.5% | -12.9% | +3.6% | |
| Q4 2019 | -0.7% | -1.4% | -42.5% | |
| Q3 2019 | -1.9% | -3.1% | -1.2% | |
| Q2 2018 | -4.8% | -1.3% | -4.6% | |
| Q2 2019 | -4.8% | -1.3% | -4.6% | |
| Q1 2019 | +6.1% | +3.9% | +4.1% | |
| Q4 2018 | -2.4% | -1.7% | -2.7% | |
| Q3 2018 | +3.7% | +3.7% | -1.9% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro